Advanced BioDesign joins ENHPATHY consortium to increase its knowledge in genetic alterations in hematologic cancers

Lyon, France, January 21, 2019 - Consortium gathers 27 organizations from 11 countries to work on enhanceropathies; will receive €4M from European Commission over next four years Lyon, France, January 21, 2020 – Advanced BioDesign, a French pre-clinical stage biotechnology company focused on the development of a new treatment against resistant cancers, today announces it has teamed up with 27 European academic and industrial organizations from 11 countries to form the multidisciplinary science consortium, ENHPATHY.

Read more

17th January 2020

Advanced BioDesign Present Preclinical Result at 61st ASH Annual Meeting

Advanced BioDesign has presented a poster at the 61st American Society of Hematology (ASH) Annual Meeting with their rational on its lead compound ABD-3001, as a treatment of patients with refractory or relapse Acute Myeloid Leukemia (r/r AML).

Read more

21st October 2019

In the press: Biotech Finances introduces Advanced BioDesign

Advanced BioDesign is honored in the French Journal - Biotech Finances - for the development of its first-in-class ALDH inhibitor in cancer targeted therapy. 

Read more

10 September 2019

Advanced BioDesign, member of ENHPATHY consortium

 

Read more

5 July 2019

Advanced BioDesign and Marseille’s Hospital allied in research against blood cancer

 

Read more